This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
More than 90% of patients with PsA who received guselkumab every 8 weeks in the DISCOVER-2 trial maintained minimal clinically important improvement in joint symptoms through week 52.
Medscape Medical News